Treatment-resistant depression

Daniel Souery, George I. Papakostas, Madhukar H. Trivedi

Research output: Contribution to journalArticle

197 Citations (Scopus)

Abstract

Treatment-resistant depression (TRD) is a common clinical occurrence among patients treated for major depressive disorder. However, a clear consensus regarding the criteria defining TRD is lacking in the psychiatric community. Many patients who are considered treatment resistant are actually mis-diagnosed or inadequately treated. Clinicians need to accurately diagnose TRD by examining primary and secondary (organic) causes of depression and acknowledging paradigm failures that contribute to a misdiagnosis of TRD. A correct determination of what constitutes TRD requires consensus on criteria of treatment response (i.e., dose, duration, and compliance) and on the number of adequate trials required before a patient is determined to be nonresponsive. Additionally, clinical validation of available staging models needs to be completed. While several studies have identified predictors of non-response, clinical studies investigating the predictors of resistance following the failure of 2 or more antidepressant trials should be pursued. In managing TRD, 3 pharmacotherapy strategies are in clinical use: optimization of antidepressant dose, augmentation/combination therapies, and switching therapies. However, the optimal strategy for treating TRD has yet to be identified. Therefore, further controlled clinical trials are essential to identify the most effective treatment strategies.

Original languageEnglish (US)
Pages (from-to)16-22
Number of pages7
JournalJournal of Clinical Psychiatry
Volume67
Issue numberSUPPL. 6
StatePublished - 2006

Fingerprint

Treatment-Resistant Depressive Disorder
Antidepressive Agents
Consensus
Therapeutics
Controlled Clinical Trials
Major Depressive Disorder
Diagnostic Errors
Compliance
Psychiatry
Depression
Drug Therapy

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Clinical Psychology

Cite this

Souery, D., Papakostas, G. I., & Trivedi, M. H. (2006). Treatment-resistant depression. Journal of Clinical Psychiatry, 67(SUPPL. 6), 16-22.

Treatment-resistant depression. / Souery, Daniel; Papakostas, George I.; Trivedi, Madhukar H.

In: Journal of Clinical Psychiatry, Vol. 67, No. SUPPL. 6, 2006, p. 16-22.

Research output: Contribution to journalArticle

Souery, D, Papakostas, GI & Trivedi, MH 2006, 'Treatment-resistant depression', Journal of Clinical Psychiatry, vol. 67, no. SUPPL. 6, pp. 16-22.
Souery D, Papakostas GI, Trivedi MH. Treatment-resistant depression. Journal of Clinical Psychiatry. 2006;67(SUPPL. 6):16-22.
Souery, Daniel ; Papakostas, George I. ; Trivedi, Madhukar H. / Treatment-resistant depression. In: Journal of Clinical Psychiatry. 2006 ; Vol. 67, No. SUPPL. 6. pp. 16-22.
@article{03077a67db6c43f2a1f1dbae597316bc,
title = "Treatment-resistant depression",
abstract = "Treatment-resistant depression (TRD) is a common clinical occurrence among patients treated for major depressive disorder. However, a clear consensus regarding the criteria defining TRD is lacking in the psychiatric community. Many patients who are considered treatment resistant are actually mis-diagnosed or inadequately treated. Clinicians need to accurately diagnose TRD by examining primary and secondary (organic) causes of depression and acknowledging paradigm failures that contribute to a misdiagnosis of TRD. A correct determination of what constitutes TRD requires consensus on criteria of treatment response (i.e., dose, duration, and compliance) and on the number of adequate trials required before a patient is determined to be nonresponsive. Additionally, clinical validation of available staging models needs to be completed. While several studies have identified predictors of non-response, clinical studies investigating the predictors of resistance following the failure of 2 or more antidepressant trials should be pursued. In managing TRD, 3 pharmacotherapy strategies are in clinical use: optimization of antidepressant dose, augmentation/combination therapies, and switching therapies. However, the optimal strategy for treating TRD has yet to be identified. Therefore, further controlled clinical trials are essential to identify the most effective treatment strategies.",
author = "Daniel Souery and Papakostas, {George I.} and Trivedi, {Madhukar H.}",
year = "2006",
language = "English (US)",
volume = "67",
pages = "16--22",
journal = "Journal of Clinical Psychiatry",
issn = "0160-6689",
publisher = "Physicians Postgraduate Press Inc.",
number = "SUPPL. 6",

}

TY - JOUR

T1 - Treatment-resistant depression

AU - Souery, Daniel

AU - Papakostas, George I.

AU - Trivedi, Madhukar H.

PY - 2006

Y1 - 2006

N2 - Treatment-resistant depression (TRD) is a common clinical occurrence among patients treated for major depressive disorder. However, a clear consensus regarding the criteria defining TRD is lacking in the psychiatric community. Many patients who are considered treatment resistant are actually mis-diagnosed or inadequately treated. Clinicians need to accurately diagnose TRD by examining primary and secondary (organic) causes of depression and acknowledging paradigm failures that contribute to a misdiagnosis of TRD. A correct determination of what constitutes TRD requires consensus on criteria of treatment response (i.e., dose, duration, and compliance) and on the number of adequate trials required before a patient is determined to be nonresponsive. Additionally, clinical validation of available staging models needs to be completed. While several studies have identified predictors of non-response, clinical studies investigating the predictors of resistance following the failure of 2 or more antidepressant trials should be pursued. In managing TRD, 3 pharmacotherapy strategies are in clinical use: optimization of antidepressant dose, augmentation/combination therapies, and switching therapies. However, the optimal strategy for treating TRD has yet to be identified. Therefore, further controlled clinical trials are essential to identify the most effective treatment strategies.

AB - Treatment-resistant depression (TRD) is a common clinical occurrence among patients treated for major depressive disorder. However, a clear consensus regarding the criteria defining TRD is lacking in the psychiatric community. Many patients who are considered treatment resistant are actually mis-diagnosed or inadequately treated. Clinicians need to accurately diagnose TRD by examining primary and secondary (organic) causes of depression and acknowledging paradigm failures that contribute to a misdiagnosis of TRD. A correct determination of what constitutes TRD requires consensus on criteria of treatment response (i.e., dose, duration, and compliance) and on the number of adequate trials required before a patient is determined to be nonresponsive. Additionally, clinical validation of available staging models needs to be completed. While several studies have identified predictors of non-response, clinical studies investigating the predictors of resistance following the failure of 2 or more antidepressant trials should be pursued. In managing TRD, 3 pharmacotherapy strategies are in clinical use: optimization of antidepressant dose, augmentation/combination therapies, and switching therapies. However, the optimal strategy for treating TRD has yet to be identified. Therefore, further controlled clinical trials are essential to identify the most effective treatment strategies.

UR - http://www.scopus.com/inward/record.url?scp=33746040866&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33746040866&partnerID=8YFLogxK

M3 - Article

VL - 67

SP - 16

EP - 22

JO - Journal of Clinical Psychiatry

JF - Journal of Clinical Psychiatry

SN - 0160-6689

IS - SUPPL. 6

ER -